JPS54115075A
(en)
*
|
1978-02-28 |
1979-09-07 |
Cho Lsi Gijutsu Kenkyu Kumiai |
Plasma etching method
|
FR2540495B1
(fr)
*
|
1983-02-07 |
1986-02-14 |
Roussel Uclaf |
Nouveaux derives de o-mercaptopropanamide et de ses homologues, leur procede de preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus
|
GB8617653D0
(en)
*
|
1986-07-18 |
1986-08-28 |
Ici Plc |
Amide derivatives
|
GB8617652D0
(en)
*
|
1986-07-18 |
1986-08-28 |
Ici Plc |
Acylanilide derivatives
|
US4921941A
(en)
*
|
1987-07-01 |
1990-05-01 |
Schering Corporation |
Orally active antiandrogens
|
US4970303A
(en)
*
|
1988-02-03 |
1990-11-13 |
Xoma Corporation |
Linking agents and methods
|
US4895715A
(en)
*
|
1988-04-14 |
1990-01-23 |
Schering Corporation |
Method of treating gynecomastia
|
US5204337A
(en)
*
|
1988-10-31 |
1993-04-20 |
Endorecherche Inc. |
Estrogen nucleus derivatives for use in inhibition of sex steroid activity
|
US5364847A
(en)
*
|
1989-03-10 |
1994-11-15 |
Endorecherche |
Inhibitors of sex steroid biosynthesis and methods for their production and use
|
ZA924811B
(en)
*
|
1991-06-28 |
1993-12-29 |
Endorecherche Inc |
Controlled release systems and low dose androgens
|
GB9214120D0
(en)
*
|
1991-07-25 |
1992-08-12 |
Ici Plc |
Therapeutic amides
|
GB9305295D0
(en)
*
|
1993-03-15 |
1993-05-05 |
Zeneca Ltd |
Therapeutic compounds
|
GB9310095D0
(en)
*
|
1993-05-17 |
1993-06-30 |
Zeneca Ltd |
Therapeutic compounds
|
JPH09508125A
(ja)
*
|
1994-01-21 |
1997-08-19 |
セプラコー,インコーポレイテッド |
光学的純正r−(−)−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成
|
DE4420777A1
(de)
|
1994-06-15 |
1995-12-21 |
Bayer Ag |
Verfahren zur Herstellung von 4-Fluorthiophenol
|
ATE232743T1
(de)
*
|
1994-06-27 |
2003-03-15 |
Neutron Therapies Inc |
Bor enthaltende hormonanaloga und verfahren fuer ihre verwendung zur bildlichen darstellung oder zum abtoeten von zellen, die hormonrezeptoren besitzen
|
US7518013B2
(en)
|
2000-08-24 |
2009-04-14 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators
|
US20050038110A1
(en)
*
|
2000-08-24 |
2005-02-17 |
Steiner Mitchell S. |
Selective androgen receptor modulators and methods of use thereof
|
US7759520B2
(en)
|
1996-11-27 |
2010-07-20 |
University Of Tennessee Research Foundation |
Synthesis of selective androgen receptor modulators
|
US7205437B2
(en)
*
|
1996-11-27 |
2007-04-17 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators
|
US6492554B2
(en)
|
2000-08-24 |
2002-12-10 |
The University Of Tennessee Research Corporation |
Selective androgen receptor modulators and methods of use thereof
|
US20090264534A1
(en)
*
|
1996-11-27 |
2009-10-22 |
Dalton James T |
Selective androgen receptor modulators
|
US6071957A
(en)
|
1996-11-27 |
2000-06-06 |
The University Of Tennessee Research Corporation |
Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
|
US6995284B2
(en)
|
2000-08-24 |
2006-02-07 |
The University Of Tennessee Research Foundation |
Synthesis of selective androgen receptor modulators
|
WO1998053826A1
(en)
*
|
1997-05-30 |
1998-12-03 |
The University Of Tennessee Research Corporation |
Non-steroidal agonist compounds and their use in male hormone therapy
|
AU7723198A
(en)
*
|
1997-06-04 |
1998-12-21 |
University Of Tennessee Research Corporation, The |
Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
|
DE19746512A1
(de)
|
1997-10-22 |
1999-04-29 |
Bayer Ag |
Verfahren zur Herstellung von Arylmercaptanen durch Hydrierung von Diaryldisulfiden
|
GB9804648D0
(en)
|
1998-03-06 |
1998-04-29 |
Zeneca Ltd |
Chemical compounds
|
GB9805520D0
(en)
|
1998-03-17 |
1998-05-13 |
Zeneca Ltd |
Chemical compounds
|
US20040186185A1
(en)
*
|
1998-05-07 |
2004-09-23 |
Steiner Mitchell S. |
Method for treatment and chemoprevention of prostate cancer
|
GB9811427D0
(en)
|
1998-05-29 |
1998-07-22 |
Zeneca Ltd |
Chemical compounds
|
CA2341711A1
(en)
*
|
1998-08-28 |
2000-03-09 |
Smithkline Beecham Corporation |
Process for making 2-amino-5-cyanophenol
|
US6472415B1
(en)
*
|
1998-12-18 |
2002-10-29 |
Biophysica, Inc. |
Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
|
US6184249B1
(en)
|
1998-12-18 |
2001-02-06 |
Biophysica, Inc. |
Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
|
HU223950B1
(hu)
|
1999-06-10 |
2005-03-29 |
Richter Gedeon Vegyészeti Gyár Rt. |
Eljárás a racém, valamint az R-(-)- és S-(+)-N-[4-ciano-3-(trifluor-metil)-fenil]-3-[(4-fluor-fenil)-szulfonil]-2-hidroxi-2-metil-propánsavamid előállítására
|
US6566372B1
(en)
*
|
1999-08-27 |
2003-05-20 |
Ligand Pharmaceuticals Incorporated |
Bicyclic androgen and progesterone receptor modulator compounds and methods
|
EP1214287B1
(en)
|
1999-09-04 |
2008-07-02 |
AstraZeneca AB |
Amides as inhibitors for pyruvate dehydrogenase
|
CA2381581A1
(en)
|
1999-09-04 |
2001-03-15 |
Astrazeneca Ab |
Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
|
EP1214295B1
(en)
|
1999-09-04 |
2006-11-02 |
AstraZeneca AB |
Hydroxyacetamidobenzenesulphonamide derivatives
|
US6713454B1
(en)
*
|
1999-09-13 |
2004-03-30 |
Nobex Corporation |
Prodrugs of etoposide and etoposide analogs
|
EP1222165A2
(en)
|
1999-10-19 |
2002-07-17 |
Nobex Corporation |
Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
|
IL149256A0
(en)
*
|
1999-10-27 |
2002-11-10 |
Nobex Corp |
Resolution of intermediates in the synthesis of substantially pure bicalutamide
|
GB9930839D0
(en)
*
|
1999-12-30 |
2000-02-16 |
Pharmacia & Upjohn Spa |
Process for treating gynecomastia
|
GB0012293D0
(en)
*
|
2000-05-23 |
2000-07-12 |
Astrazeneca Ab |
Pharmaceutical combination
|
GB0012291D0
(en)
*
|
2000-05-23 |
2000-07-12 |
Astrazeneca Ab |
Pharmaceutical combination
|
TWI270545B
(en)
|
2000-05-24 |
2007-01-11 |
Sugen Inc |
Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
US6828458B2
(en)
|
2000-05-25 |
2004-12-07 |
Biophysica, Inc. |
Topical antiandrogen for hair loss and other hyperandrogenic conditions
|
GB0016426D0
(en)
*
|
2000-07-05 |
2000-08-23 |
Astrazeneca Ab |
Pharmaceutical combination
|
WO2003079972A2
(en)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US6998500B2
(en)
|
2000-08-24 |
2006-02-14 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US8008348B2
(en)
|
2001-12-06 |
2011-08-30 |
University Of Tennessee Research Foundation |
Treating muscle wasting with selective androgen receptor modulators
|
SI1401801T1
(sl)
*
|
2000-08-24 |
2007-04-30 |
Univ Tennessee Res Foundation |
Selektivni modulatorji androgenskega receptorja in postopki za njihovo uporabo
|
US7645898B2
(en)
|
2000-08-24 |
2010-01-12 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and method of use thereof
|
US7855229B2
(en)
|
2000-08-24 |
2010-12-21 |
University Of Tennessee Research Foundation |
Treating wasting disorders with selective androgen receptor modulators
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7026500B2
(en)
*
|
2000-08-24 |
2006-04-11 |
University Of Tennessee Research Foundation |
Halogenated selective androgen receptor modulators and methods of use thereof
|
US7919647B2
(en)
|
2000-08-24 |
2011-04-05 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US8445534B2
(en)
|
2000-08-24 |
2013-05-21 |
University Of Tennessee Research Foundation |
Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
|
US20040260108A1
(en)
*
|
2001-06-25 |
2004-12-23 |
Dalton James T. |
Metabolites of selective androgen receptor modulators and methods of use thereof
|
US20070173546A1
(en)
*
|
2000-08-24 |
2007-07-26 |
Dalton James T |
Selective androgen receptor modulators and method of use thereof
|
US6838484B2
(en)
|
2000-08-24 |
2005-01-04 |
University Of Tennessee Research Foundation |
Formulations comprising selective androgen receptor modulators
|
US20030232792A1
(en)
*
|
2000-08-24 |
2003-12-18 |
Dalton James T. |
Selective androgen receptor modulators and methods of use thereof
|
PL361705A1
(en)
*
|
2000-09-21 |
2004-10-04 |
Bristol-Myers Squibb Company |
Process for the preparation of n-(substituted phenyl)-3-alkyl-, aryl- and heteroarylsulfonyl-2-hydroxy-2-alkyl- and haloalkylpropanamide compounds
|
SI3351246T1
(sl)
|
2001-02-19 |
2019-08-30 |
Novartis Pharma Ag |
Derivat rapamicina za zdravljenje trdnega tumorja, povezanega z deregulirano angiogenezo
|
MXPA03007641A
(es)
*
|
2001-02-27 |
2003-12-04 |
Astrazeneca Ab |
Formulacion farmaceutica.
|
US6479692B1
(en)
|
2001-05-02 |
2002-11-12 |
Nobex Corporation |
Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
|
PL392652A1
(pl)
|
2001-05-16 |
2010-12-06 |
Novartis Ag |
Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację
|
AU2002312431A1
(en)
*
|
2001-06-13 |
2002-12-23 |
Biogal Gyogyszergyar Rt. |
Novel process for preparing rac-bicalutamide and its intermediates
|
US7102026B2
(en)
*
|
2001-06-13 |
2006-09-05 |
Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság |
Process for preparing and isolating rac-bicalutamide and its intermediates
|
US20060287282A1
(en)
*
|
2001-06-25 |
2006-12-21 |
Steiner Mitchell S |
Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
|
US7015253B2
(en)
*
|
2001-07-10 |
2006-03-21 |
American Medical Systems, Inc. |
Regimen for treating prostate tissue and surgical kit for use in the regimen
|
US20060004042A1
(en)
*
|
2001-08-23 |
2006-01-05 |
Dalton James T |
Formulations comprising selective androgen receptor modulators
|
SE0103424D0
(sv)
*
|
2001-10-15 |
2001-10-15 |
Astrazeneca Ab |
Pharmaceutical formulation
|
AT410545B
(de)
*
|
2001-11-07 |
2003-05-26 |
Dsm Fine Chem Austria Gmbh |
Verfahren zur herstellung von chiralen alpha-hydroxycarbonsäuren
|
GB0128510D0
(en)
*
|
2001-11-28 |
2002-01-23 |
Novartis Ag |
Organic compounds
|
CA2469340A1
(en)
|
2001-12-06 |
2003-06-19 |
Gtx Inc. |
Treating muscle wasting with selective androgen receptor modulators
|
US8853266B2
(en)
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
US7595402B2
(en)
|
2003-12-16 |
2009-09-29 |
Gtx, Inc. |
Prodrugs of selective androgen receptor modulators and methods of use thereof
|
US20070161608A1
(en)
*
|
2001-12-06 |
2007-07-12 |
Dalton James T |
Selective androgen receptor modulators for treating muscle wasting
|
SI1462442T1
(sl)
*
|
2001-12-13 |
2010-01-29 |
Sumitomo Chemical Co |
Kristali bikalutamida in postopek za njihovo pripravo
|
CA2475108A1
(en)
*
|
2002-02-07 |
2003-08-14 |
Mitchell S. Steiner |
Treating benign prostate hyperplasia with sarms
|
KR101088352B1
(ko)
*
|
2002-02-28 |
2011-11-30 |
유니버시티 오브 테네시 리서치 파운데이션 |
다치환된 선택적 안드로겐 수용체 조절자 및 이를 사용하는 방법
|
US7803970B2
(en)
|
2002-02-28 |
2010-09-28 |
University Of Tennessee Research Foundation |
Multi-substitued selective androgen receptor modulators and methods of use thereof
|
US7344700B2
(en)
|
2002-02-28 |
2008-03-18 |
University Of Tennessee Research Corporation |
Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
|
US7772433B2
(en)
|
2002-02-28 |
2010-08-10 |
University Of Tennessee Research Foundation |
SARMS and method of use thereof
|
WO2003074471A1
(en)
*
|
2002-02-28 |
2003-09-12 |
University Of Tennessee Research Foundation |
Haloacetamide and azide substituted compounds and methods of use thereof
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
PL372103A1
(en)
|
2002-05-16 |
2005-07-11 |
Novartis Ag |
Use of edg receptor binding agents in cancer
|
US7741371B2
(en)
|
2002-06-17 |
2010-06-22 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
CA2489182A1
(en)
|
2002-06-17 |
2003-12-24 |
University Of Tennessee Research Foundation |
N-bridged selective androgen receptor modulators and methods of use thereof
|
AU2003248052A1
(en)
|
2002-07-12 |
2004-02-02 |
Yamanouchi Pharmaceutical Co., Ltd. |
N-phenyl-(2r,5s)dimethylpiperadine derivative
|
US20040063782A1
(en)
*
|
2002-09-27 |
2004-04-01 |
Westheim Raymond J.H. |
Bicalutamide forms
|
US6818766B2
(en)
|
2002-10-02 |
2004-11-16 |
Synthon Bv |
Process for making bicalutamide and intermediates thereof
|
CN1726193A
(zh)
*
|
2002-10-15 |
2006-01-25 |
田纳西大学研究基金会 |
杂环选择性雄激素受体调节剂及其使用方法
|
US20040197928A1
(en)
*
|
2002-10-15 |
2004-10-07 |
Dalton James T. |
Method for detecting selective androgen receptor modulators
|
CA2502209A1
(en)
*
|
2002-10-15 |
2004-04-29 |
University Of Tennessee Research Foundation |
Methylene-bridged selective androgen receptor modulators and methods of use thereof
|
CA2501797A1
(en)
*
|
2002-10-15 |
2004-04-29 |
Gtx, Inc. |
Treating obesity with selective androgen receptor modulators
|
US20060276539A1
(en)
*
|
2002-10-16 |
2006-12-07 |
Dalton James T |
Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
|
AU2003287079A1
(en)
*
|
2002-10-16 |
2004-05-04 |
Gtx, Inc. |
Treating androgen decline in aging male (adam)-associated conditions with sarms
|
US20040087810A1
(en)
*
|
2002-10-23 |
2004-05-06 |
Dalton James T. |
Irreversible selective androgen receptor modulators and methods of use thereof
|
PL201540B1
(pl)
*
|
2002-10-30 |
2009-04-30 |
Inst Farmaceutyczny |
Sposób wytwarzania wysokiej czystości N-(4-cyjano-3-trifluorometylofenylo)-3-(4-fluorofenylosulfonylo)-2-hydroksy-2-metylopropanamidu
|
PL201541B1
(pl)
*
|
2002-10-30 |
2009-04-30 |
Inst Farmaceutyczny |
Sposób wytwarzania N-(4-cyjano-3-trifluorometylofenylo)-2,3-epoksy-2-metylopropanamidu
|
US8309603B2
(en)
|
2004-06-07 |
2012-11-13 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
AU2004204800B8
(en)
|
2003-01-13 |
2011-05-26 |
University Of Tennessee Research Foundation |
Large-scale synthesis of selective androgen receptor modulators
|
US7332525B2
(en)
*
|
2003-01-17 |
2008-02-19 |
Castle Erik P |
Method of treatment of prostate cancer and composition for treatment thereof
|
AU2003209667A1
(en)
*
|
2003-02-21 |
2004-09-09 |
Hetero Drugs Limited |
Bicalutamide polymorphs
|
US20040167103A1
(en)
*
|
2003-02-24 |
2004-08-26 |
Dalton James T. |
Haloacetamide and azide substituted compounds and methods of use thereof
|
US7709525B2
(en)
|
2003-02-27 |
2010-05-04 |
Wisconsin Alumni Research Foundation |
Chroman-derived anti-androgens for treatment of androgen-mediated disorders
|
US20050008691A1
(en)
*
|
2003-05-14 |
2005-01-13 |
Arturo Siles Ortega |
Bicalutamide compositions
|
CA2529232A1
(en)
*
|
2003-06-25 |
2005-02-03 |
Teva Gyogyszergyar Reszvenytarsasag |
Process for purifying and isolating rac-bicalutamide
|
MXPA05013619A
(es)
*
|
2003-06-27 |
2006-03-10 |
Orion Corp |
Nuevos compuestos.
|
FI20030958A0
(fi)
*
|
2003-06-27 |
2003-06-27 |
Orion Corp |
Uusia yhdisteitä
|
CN100462353C
(zh)
*
|
2003-06-27 |
2009-02-18 |
奥赖恩公司 |
用作雄激素受体调节剂的丙酰胺衍生物
|
JP4681548B2
(ja)
|
2003-07-22 |
2011-05-11 |
アステックス・セラピューティクス・リミテッド |
3,4−ジ置換1h−ピラゾール化合物および、そのサイクリン依存性キナーゼ(cdk)およびグリコーゲン・シンセターゼ・キナーゼ−3(gsk−3)調節剤としての使用
|
JP2005060302A
(ja)
*
|
2003-08-12 |
2005-03-10 |
Sumitomo Chemical Co Ltd |
N−メタクリロイル−4−シアノ−3−トリフルオロメチルアニリンの製造方法および安定化方法
|
CN1838956A
(zh)
*
|
2003-08-22 |
2006-09-27 |
配体药物公司 |
作为雄激素受体调节剂化合物的6-环氨基-2-喹啉酮衍生物
|
MXPA06002462A
(es)
*
|
2003-10-14 |
2006-06-20 |
Gtx Inc |
Tratamiento de desordenes relacionados con huesos con moduladores del receptor de angrogeno selectivo.
|
TW200523235A
(en)
*
|
2003-10-15 |
2005-07-16 |
Gtx Inc |
Anti-cancer compounds and methods of use thereof
|
EP1689383B1
(en)
|
2003-11-19 |
2012-10-31 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
WO2005060951A2
(en)
*
|
2003-12-19 |
2005-07-07 |
Bionaut Pharmaceuticals, Inc. |
Anti-neoplastic agents, combination therapies and related methods
|
BRPI0507670A
(pt)
|
2004-02-13 |
2007-07-17 |
Warner Lambert Co |
moduladores do receptor de androgênio
|
US8519158B2
(en)
*
|
2004-03-12 |
2013-08-27 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
EP2065368A1
(en)
|
2004-04-07 |
2009-06-03 |
Novartis Ag |
Inhibitors of IAP
|
WO2005100305A1
(en)
|
2004-04-13 |
2005-10-27 |
Warner-Lambert Company Llc |
Androgen modulators
|
EP1740533A1
(en)
|
2004-04-22 |
2007-01-10 |
Warner-Lambert Company LLC |
Androgen modulators
|
US20110237664A1
(en)
*
|
2004-06-07 |
2011-09-29 |
Dalton James T |
Selective androgen receptor modulators for treating diabetes
|
WO2005120483A2
(en)
*
|
2004-06-07 |
2005-12-22 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
ITMI20041222A1
(it)
|
2004-06-17 |
2004-09-17 |
Cosma S P A |
Procedimento perfezionato per la sintesi di bicalutamide
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
MXPA06015169A
(es)
|
2004-07-08 |
2007-08-21 |
Warner Lambert Co |
Moduladores de androgenos.
|
ES2368838T3
(es)
|
2004-07-14 |
2011-11-22 |
Sumitomo Chemical Company Limited |
Procedimiento para la cristalización de la bicalutamida.
|
US20060258628A1
(en)
*
|
2004-07-20 |
2006-11-16 |
Steiner Mitchell S |
Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
|
US20060135468A1
(en)
*
|
2004-09-02 |
2006-06-22 |
Bionaut Pharmaceuticals, Inc. |
Treatment of refractory cancers using NA+/K+ ATPase inhibitors
|
EP1789090A2
(en)
*
|
2004-09-02 |
2007-05-30 |
Bionaut Pharmaceuticals, Inc. |
Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
|
ATE509630T1
(de)
*
|
2004-09-02 |
2011-06-15 |
Bionaut Pharmaceuticals Inc |
Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern
|
US20080027010A1
(en)
*
|
2004-09-02 |
2008-01-31 |
Bionaut Pharmaceuticals, Inc. |
Treatment of refractory cancers using Na+/K+-ATPase inhibitors
|
US20070105790A1
(en)
*
|
2004-09-02 |
2007-05-10 |
Bionaut Pharmaceuticals, Inc. |
Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
|
EP1812010A2
(en)
*
|
2004-10-18 |
2007-08-01 |
BTG International Limited |
Use of na+/ k+-atpase inhibitors and antagonists thereof
|
WO2006069098A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Elan Pharma International Ltd. |
Nanoparticulate bicalutamide formulations
|
RU2436575C2
(ru)
*
|
2005-01-21 |
2011-12-20 |
Астекс Терапьютикс Лимитед |
Соединения для использования в фармацевтике
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
ES2552338T3
(es)
|
2005-01-21 |
2015-11-27 |
Astex Therapeutics Limited |
Compuestos farmacéuticos
|
AU2005329762A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Usv Limited |
Process for preparation of bicalutamide
|
TW200724139A
(en)
|
2005-05-05 |
2007-07-01 |
Warner Lambert Co |
Androgen modulators
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US7709516B2
(en)
|
2005-06-17 |
2010-05-04 |
Endorecherche, Inc. |
Helix 12 directed non-steroidal antiandrogens
|
BRPI0609191B8
(pt)
*
|
2005-06-17 |
2021-05-25 |
Ligand Pharm Inc |
métodos e compostos moduladores de receptor de androgênio
|
CA2513356A1
(en)
*
|
2005-07-26 |
2007-01-26 |
Apotex Pharmachem Inc. |
Process for production of bicalutamide
|
BRPI0616755A2
(pt)
|
2005-09-27 |
2011-06-28 |
Novartis Ag |
compostos de carboxiamina e métodos de uso dos mesmos
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US9006224B2
(en)
|
2005-11-21 |
2015-04-14 |
Novartis Ag |
Neuroendocrine tumor treatment
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
CA2635461A1
(en)
*
|
2005-12-27 |
2007-07-05 |
Dabur Pharma Limited |
An improved process for preparation of bicalutamide
|
RU2435756C2
(ru)
*
|
2006-03-03 |
2011-12-10 |
Орион Корпорейшн |
Избирательные андрогенные рецепторные модуляторы
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
MX2008012492A
(es)
|
2006-03-29 |
2008-12-12 |
Univ California |
Compuestos de diariltiohidantoina.
|
CN101415409B
(zh)
|
2006-04-05 |
2012-12-05 |
诺瓦提斯公司 |
用于治疗癌症的治疗剂的组合
|
RU2452492C2
(ru)
|
2006-04-05 |
2012-06-10 |
Новартис Аг |
КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
|
KR20090007635A
(ko)
|
2006-05-09 |
2009-01-19 |
노파르티스 아게 |
철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
|
WO2008013791A2
(en)
*
|
2006-07-24 |
2008-01-31 |
University Of Delaware |
Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
|
US9844528B2
(en)
|
2006-08-24 |
2017-12-19 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US10010521B2
(en)
|
2006-08-24 |
2018-07-03 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US9730908B2
(en)
|
2006-08-24 |
2017-08-15 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
CN101528214B
(zh)
|
2006-08-24 |
2013-06-05 |
田纳西大学研究基金会 |
取代的n-酰基苯胺及其使用方法
|
EP2081933B1
(en)
|
2006-09-29 |
2011-03-23 |
Novartis AG |
Pyrazolopyrimidines as pi3k lipid kinase inhibitors
|
WO2008044033A1
(en)
*
|
2006-10-11 |
2008-04-17 |
Astrazeneca Ab |
Amide derivatives
|
JP5528807B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
EP2094643B1
(en)
|
2006-12-01 |
2012-02-29 |
Bristol-Myers Squibb Company |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
US9232959B2
(en)
|
2007-01-02 |
2016-01-12 |
Aquabeam, Llc |
Multi fluid tissue resection methods and devices
|
JP5369336B2
(ja)
*
|
2007-01-02 |
2013-12-18 |
アクアビーム エルエルシー |
前立腺の疾患を治療するための侵襲性が最小である方法及びデバイス
|
US12290277B2
(en)
|
2007-01-02 |
2025-05-06 |
Aquabeam, Llc |
Tissue resection with pressure sensing
|
JP2010519209A
(ja)
|
2007-02-15 |
2010-06-03 |
ノバルティス アーゲー |
癌を処置するためのlbh589と他の治療剤の組み合わせ剤
|
US20080245375A1
(en)
*
|
2007-04-05 |
2008-10-09 |
Medtronic Vascular, Inc. |
Benign Prostatic Hyperplasia Treatments
|
US9284345B2
(en)
|
2007-04-12 |
2016-03-15 |
Endorecherche, Inc. |
17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
|
EP2359828A1
(en)
|
2007-06-06 |
2011-08-24 |
University of Maryland, Baltimore |
HDAC inhibitors and hormone targeted drugs for the treatment of cancer
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
US20090076158A1
(en)
*
|
2007-09-13 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bicalutamide
|
TWI469971B
(zh)
|
2007-10-26 |
2015-01-21 |
Univ California |
二芳基乙內醯脲類化合物
|
EP2259742B1
(en)
*
|
2008-03-06 |
2020-01-01 |
AquaBeam LLC |
Tissue ablation and cautery with optical energy carried in fluid stream
|
JP5490092B2
(ja)
|
2008-03-24 |
2014-05-14 |
ノバルティス アーゲー |
アリールスルホンアミドをベースとするマトリクスメタロプロテアーゼ阻害剤
|
MX2010010502A
(es)
|
2008-03-26 |
2010-10-26 |
Novartis Ag |
Inhibidores de desacetilasas b a base de hidroxamato.
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
PT2391366E
(pt)
|
2009-01-29 |
2013-02-05 |
Novartis Ag |
Benzimidazoles substituídos para o tratamento de astrocitomas
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
US9848904B2
(en)
|
2009-03-06 |
2017-12-26 |
Procept Biorobotics Corporation |
Tissue resection and treatment with shedding pulses
|
WO2014127242A2
(en)
|
2013-02-14 |
2014-08-21 |
Procept Biorobotics Corporation |
Aquablation aquabeam eye surgery methods and apparatus
|
WO2016037137A1
(en)
|
2014-09-05 |
2016-03-10 |
Procept Biorobotics Corporation |
Physician controlled tissue resection integrated with treatment mapping of target organ images
|
WO2010116342A2
(en)
*
|
2009-04-10 |
2010-10-14 |
Consiglio Nazionale Delle Ricerche |
Non-steroidal compounds for androgen receptor modulation
|
ITBO20090235A1
(it)
*
|
2009-04-10 |
2010-10-11 |
Consiglio Nazionale Ricerche |
Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi
|
MY155570A
(en)
|
2009-06-26 |
2015-10-30 |
Novartis Ag |
1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
|
US8450374B2
(en)
*
|
2009-06-29 |
2013-05-28 |
University Of Delaware |
Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
IN2012DN01453A
(en, 2012)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
IN2012DN01693A
(en, 2012)
|
2009-08-26 |
2015-06-05 |
Novartis Ag |
|
MX2012002997A
(es)
|
2009-09-10 |
2012-08-01 |
Novartis Ag |
Derivados de eter de los heteroarilos biciclicos.
|
AR078793A1
(es)
|
2009-10-27 |
2011-12-07 |
Orion Corp |
Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
|
ES2487628T3
(es)
|
2009-11-04 |
2014-08-22 |
Novartis Ag |
Derivados de sulfonamida heterocíclica útiles como inhibidores de MEK
|
US20120289501A1
(en)
|
2009-11-25 |
2012-11-15 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
WO2011064663A1
(en)
|
2009-11-25 |
2011-06-03 |
Festuccia, Claudio |
Combination treatment employing belinostat and bicalutamide
|
EA201200823A1
(ru)
|
2009-12-08 |
2013-02-28 |
Новартис Аг |
Гетероциклические производные сульфонамидов
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
CN101759597B
(zh)
*
|
2009-12-31 |
2013-09-04 |
上海康鹏化学有限公司 |
2-三氟甲基-4-氨基苯腈的制备方法
|
AU2011203832A1
(en)
*
|
2010-01-11 |
2012-08-23 |
Gtx, Inc. |
Methods of treating Meibomian gland dysfunction
|
EP2582681A1
(en)
|
2010-06-17 |
2013-04-24 |
Novartis AG |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
CN102947274A
(zh)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
FI20105806A0
(fi)
|
2010-07-15 |
2010-07-15 |
Medeia Therapeutics Ltd |
Uudet aryyliamidijohdannaiset, joilla on antiandrogeenisia ominaisuuksia
|
EP2627648A1
(en)
|
2010-09-16 |
2013-08-21 |
Novartis AG |
17aHYDROXYLASE/C17,20-LYASE INHIBITORS
|
US8895772B2
(en)
|
2010-09-29 |
2014-11-25 |
Shilpa Medicare Limited |
Process for preparing bicalutamide
|
WO2012109387A1
(en)
|
2011-02-08 |
2012-08-16 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
JP2014507465A
(ja)
|
2011-03-08 |
2014-03-27 |
ノバルティス アーゲー |
フルオロフェニル二環式ヘテロアリール化合物
|
CN103492372B
(zh)
|
2011-04-21 |
2015-09-30 |
奥赖恩公司 |
调节雄激素受体的甲酰胺类化合物
|
KR20140025492A
(ko)
|
2011-04-28 |
2014-03-04 |
노파르티스 아게 |
17α-히드록실라제/C17,20-리아제 억제제
|
EP2709991B1
(en)
|
2011-05-16 |
2020-09-02 |
Genzyme Corporation |
Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia
|
JP2014517004A
(ja)
|
2011-06-09 |
2014-07-17 |
ノバルティス アーゲー |
複素環スルホンアミド誘導体
|
EP2721008B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
|
EP2721007B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Cyclohexyl isoquinolinone compounds
|
CN103608349A
(zh)
|
2011-06-27 |
2014-02-26 |
诺瓦提斯公司 |
四氢-吡啶并-嘧啶衍生物的固体形式和盐
|
EA026655B1
(ru)
|
2011-09-15 |
2017-05-31 |
Новартис Аг |
6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
|
EP2785717B1
(en)
|
2011-11-29 |
2016-01-13 |
Novartis AG |
Pyrazolopyrrolidine compounds
|
JP6309454B2
(ja)
|
2011-11-30 |
2018-04-11 |
アストラゼネカ アクチボラグ |
癌の併用処置
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
SI2794600T1
(en)
|
2011-12-22 |
2018-03-30 |
Novartis Ag |
2,3-Dihydro-benzo (1,4) oxazine derivatives and related compounds as phosphoinositide-3 kinase inhibitors (PI3K) for the treatment, e.g. rheumatoid arthritis
|
WO2013096055A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
EA201491268A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
|
US9126979B2
(en)
|
2011-12-23 |
2015-09-08 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
CN104136428A
(zh)
|
2011-12-23 |
2014-11-05 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
EA201491260A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
|
EA029007B1
(ru)
|
2012-01-13 |
2018-01-31 |
Аранда Фарма Лтд |
Новые гетероариламидные производные, обладающие антиандрогенными свойствами
|
WO2013104829A1
(en)
|
2012-01-13 |
2013-07-18 |
Medeia Therapeutics Ltd |
Novel arylamide derivatives having antiandrogenic properties
|
WO2013104831A1
(en)
|
2012-01-13 |
2013-07-18 |
Medeia Therapeutics Ltd |
Arylamide derivatives having antiandrogenic properties
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
JP6080872B2
(ja)
|
2012-02-29 |
2017-02-15 |
プロセプト バイオロボティクス コーポレイション |
自動化された画像誘導組織切除および治療
|
EP3964513A1
(en)
|
2012-04-03 |
2022-03-09 |
Novartis AG |
Combination products with tyrosine kinase inhibitors and their use
|
US20150057452A1
(en)
*
|
2012-04-04 |
2015-02-26 |
Catylix, Inc. |
Selective androgen receptor modulators
|
AU2013204533B2
(en)
|
2012-04-17 |
2017-02-02 |
Astrazeneca Ab |
Crystalline forms
|
US20130310387A1
(en)
|
2012-05-16 |
2013-11-21 |
Novartis Ag |
Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
|
US9365576B2
(en)
|
2012-05-24 |
2016-06-14 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
CN110840870A
(zh)
|
2012-07-13 |
2020-02-28 |
Gtx公司 |
选择性雄激素受体调节剂在治疗转移性和难治性乳癌中的应用
|
BR112015003058A2
(pt)
|
2012-08-13 |
2017-07-04 |
Novartis Ag |
derivados bicíclicos de heteroaril cicloalquildiamina como inibidores de tirosina quinases do baço (syk)
|
NZ706635A
(en)
|
2012-10-02 |
2018-08-31 |
Gilead Sciences Inc |
Inhibitors of histone demethylases
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
RU2510392C1
(ru)
*
|
2012-12-21 |
2014-03-27 |
Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) |
Сокристаллическая форма бикалутамида
|
WO2014115080A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
AP2015008676A0
(en)
|
2013-02-27 |
2015-08-31 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
CN105764436B
(zh)
|
2013-09-06 |
2019-04-26 |
普罗赛普特生物机器人公司 |
利用致脱脉冲的用于消融组织的装置
|
RU2675105C9
(ru)
|
2013-09-22 |
2019-01-09 |
Саншайн Лейк Фарма Ко., Лтд. |
Замещенные аминопиримидиновые соединения и способы их использования
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
US9682960B2
(en)
|
2013-12-19 |
2017-06-20 |
Endorecherche, Inc. |
Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
|
CN103772238B
(zh)
*
|
2014-01-24 |
2017-03-22 |
苏州伊莱特新药研发有限公司 |
一类新的含酯基芳香丙酰胺化合物及其制备方法和用途
|
US9399637B2
(en)
|
2014-03-28 |
2016-07-26 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
TW201625535A
(en)
|
2014-03-31 |
2016-07-16 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
WO2015196144A2
(en)
|
2014-06-20 |
2015-12-23 |
England Pamela M |
Androgen receptor antagonists
|
CN106572864B
(zh)
|
2014-06-30 |
2020-06-09 |
普罗赛普特生物机器人公司 |
流体射流组织切除和寒凝装置
|
CN104151197B
(zh)
*
|
2014-07-25 |
2017-02-22 |
苏州伊莱特新药研发有限公司 |
芳香丙酰胺类化合物及其制备方法和应用
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
BR112017001695A2
(pt)
|
2014-07-31 |
2017-11-21 |
Novartis Ag |
terapia de combinação
|
MX2017002451A
(es)
|
2014-08-27 |
2017-05-23 |
Gilead Sciences Inc |
Compuestos y metodos para inhibir histona desmetilasas.
|
WO2016079521A1
(en)
|
2014-11-20 |
2016-05-26 |
University College Cardiff Consultants Limited |
Androgen receptor modulators and their use as anti-cancer agents
|
WO2016079522A1
(en)
|
2014-11-20 |
2016-05-26 |
University College Cardiff Consultants Limited |
Androgen receptor modulators and their use as anti-cancer agents
|
US9834507B2
(en)
|
2015-04-21 |
2017-12-05 |
University Of Tennessee Research Foundation |
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
EP3285757B1
(en)
|
2015-04-21 |
2021-09-22 |
Oncternal Therapeutics, Inc. |
Selective androgen receptor degrader (sard) ligands and methods of use thereof
|
US10441570B2
(en)
|
2015-04-21 |
2019-10-15 |
University Of Tennessee Research Foundation |
Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
|
US10035763B2
(en)
|
2015-04-21 |
2018-07-31 |
Gtx, Inc. |
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
US10865184B2
(en)
|
2015-04-21 |
2020-12-15 |
University Of Tennessee Research Foundation |
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
US10654809B2
(en)
|
2016-06-10 |
2020-05-19 |
University Of Tennessee Research Foundation |
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
RU2689988C2
(ru)
|
2015-04-21 |
2019-05-30 |
Джи Ти Икс, ИНК. |
Селективные лиганды-разрушители андрогенных рецепторов (sard) и способы их применения
|
US10093613B2
(en)
|
2015-04-21 |
2018-10-09 |
Gtx, Inc. |
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
US10806720B2
(en)
|
2015-04-21 |
2020-10-20 |
University Of Tennessee Research Foundation |
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
US10017471B2
(en)
|
2015-04-21 |
2018-07-10 |
University Of Tennessee Research Foundation |
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
US11230523B2
(en)
|
2016-06-10 |
2022-01-25 |
University Of Tennessee Research Foundation |
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
CN106748884B
(zh)
*
|
2016-12-13 |
2021-08-20 |
山西振东制药股份有限公司 |
一种比卡鲁胺中间体的制备方法
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
JP7021356B2
(ja)
|
2017-12-21 |
2022-02-16 |
ヘフェイ インスティテューツ オブ フィジカル サイエンス, チャイニーズ アカデミー オブ サイエンシーズ |
ピリミジン誘導体系キナーゼ阻害剤類
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
MA52642A
(fr)
|
2018-05-14 |
2021-03-24 |
Nuvation Bio Inc |
Composés ciblant des récepteurs hormonaux nucléaires anticancéreux
|
US12202815B2
(en)
|
2018-09-05 |
2025-01-21 |
University Of Tennessee Research Foundation |
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
EP3876929A1
(en)
|
2018-11-05 |
2021-09-15 |
Pfizer Inc. |
Combination for treating cancer
|
CN109438297B
(zh)
*
|
2018-12-03 |
2021-05-14 |
昆明积大制药股份有限公司 |
雄激素受体拮抗剂、其制备方法及其应用
|
EP3956309A4
(en)
|
2019-04-19 |
2023-06-07 |
Ligand Pharmaceuticals Inc. |
CRYSTALLINE FORMS AND METHODS FOR PRODUCING CRYSTALLINE FORMS OF A COMPOUND
|
SG11202111402PA
(en)
|
2019-05-14 |
2021-11-29 |
Nuvation Bio Inc |
Anti-cancer nuclear hormone receptor-targeting compounds
|
US12404332B2
(en)
|
2020-03-13 |
2025-09-02 |
Research Development Foundation |
Methods for diagnosing and treating cancers
|
MX2023001823A
(es)
|
2020-08-13 |
2023-03-13 |
Pfizer |
Terapia de combinacion.
|
MX2023011294A
(es)
|
2021-03-24 |
2023-10-05 |
Pfizer |
Combinacion de talazoparib y un antiandrogeno para el tratamiento del cancer de prostata sensible a la castracion metastasico mutado en el gen ddr.
|
TWI883565B
(zh)
|
2022-10-02 |
2025-05-11 |
美商輝瑞大藥廠 |
用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
|
TW202425976A
(zh)
|
2022-12-17 |
2024-07-01 |
美商輝瑞大藥廠 |
用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
|
WO2025045058A1
(zh)
*
|
2023-08-28 |
2025-03-06 |
中国药科大学 |
作为雄激素受体拮抗剂的化合物
|
WO2025067483A1
(zh)
*
|
2023-09-28 |
2025-04-03 |
中国药科大学 |
酰胺类化合物
|